PMID: 25739191Jan 1, 2014Paper

Preclinical study of safety of the new pharmacological substance AV0012 to treat hepatitis C

Eksperimental'naia i klinicheskaia farmakologiia
A A IvashchenkoI É Kuznetsov

Abstract

Pharmacological safety of a new type of HCV inhibitor, AV0012, was studied including acute, subchronic and chronic toxicity in mice, rats and monkeys. Genotoxicity was assessed using the Ames test and the chromosomal aberrations assay in the bone marrow cells of mice. It is established that AV0012 has low toxicity in SHK line mice, Wistar line rats, and monkey of Rhesus macaques species. Results obtained in the study of genetic toxicity showed that AV0012 exhibits no mutagenic activity. Data on general toxicity and mutagenicity discussed in this paper, together with data on 1 the pharmacological activity, pharmacokinetics, and metabolism published previously, allow us to consider AV0012 as a candidate drug for clinical research phase I.

Related Concepts

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology
J D PaulsonD Newman
Medicina Experimentalis. International Journal of Experimental Medicine
A K HRENOFF, H H ANDERSON
American Journal of Hospital Pharmacy
T H Connor, R W Anderson
Medicina Experimentalis. International Journal of Experimental Medicine
A K HRENOFF
© 2022 Meta ULC. All rights reserved